白雲山(00874.HK)董事會批准廣藥基金出資不超6.90億元參與設立廣藥創投基金
格隆匯12月19日丨白雲山(00874.HK)公吿,於2023年12月19日,董事會批准廣藥基金出資不超過人民幣6.90億元參與設立廣藥創投基金,並同意廣藥基金與廣藥資本及產投專項母基金簽署合夥協議。同日,廣藥基金與廣藥資本及產投專項母基金簽署合夥協議。
廣藥創投基金擬於中國廣州註冊,從事股權投資、投資管理、資產管理、創業投資等活動,主要聚焦生物醫藥健康領域的股權投資。
本次投資符合廣藥基金的投資方向,有利於分散投資風險、提高投資效率,將促進公司加速在生物醫藥健康產業領域的轉型升級、實現快速發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.